NAVB News and Press, Navidea Biopharmaceuticals Inc. From 06/02/23

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received a Notice (the “Notice”) on June 1, 2023...

In line with the Company’s Fix, Fund, Propel approach, Jill Bieker Stefanelli, Ph.D. joins Board, adding precision medicine and product development depth in support of stated strategy to advance innovative technology to market. Separately, Alexander L. Cappello steps down. Navide...

2023-05-23 07:30:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off the day with a breakdown of the biggest pre-market stock movers traders need to watch on Tuesday! Moving stocks are earnings reports, insider buying, delisting pla...

Following the Company’s Fix, Fund, Propel approach, the sale of Preferred Shares totaling $1.1 million to new existing investors underscores improved confidence in Navidea’s progress toward advancing its innovative technology to market. Navidea Biopharmaceuticals, Inc. (NY...

2023-05-11 17:42:35 ET Navidea Biopharmaceuticals ( NYSE: NAVB ) said Thursday it promoted Michael Sherman Blue to the position of chief medical officer. Blue will report directly to the company’s board of directors. Press Release . F...

Following the Company’s Fix, Fund, Propel approach, Dr. Blue’s promotion highlights deep expertise, commitment to quality, and focus on advancement of innovative technology to market. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the &#...

The company introduces Fix, Fund, Propel approach to further focus on strategic objectives; will publish financial and corporate development highlights via press release in lieu of conference call and webcast for Q1 2023 results. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (&...

Fresh capital for funding Phase IIb and Phase III trials, expands growth, and fuels shareholder value Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agent...

The Asset Purchase Agreement allows Meilleur Technologies, Inc. to develop and commercialize markets while Navidea Biopharmaceuticals, Inc. receives additional liquidity for focused growth. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Co...

2023-03-31 05:00:30 ET Navidea Biopharmaceuticals ( NYSE: NAVB ) said Michael Rosol stepped down as chief medical officer and the company has hired G2G Ventures as executive consultants to help with its growth plans. The company noted that the chief medical officer's ...